Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896663068> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W2896663068 endingPage "vii11" @default.
- W2896663068 startingPage "vii11" @default.
- W2896663068 abstract "Main objective in palliative therapy for patients with metastatic breast cancer (MBC) is prolonged survival and maintenance of quality of life. In ER-positive/HER2-negative MBC, sequential endocrine therapy is one of the most important treatment strategy for patients who have hormone-responsive and no life-threatening disease. However, the optimal sequential endocrine therapy is not established. Aromatase inhibitor, selective ER modulator, selective ER down-regulator and CDK4/6 inhibitor + aromatase inhibitor are candidates as 1st line endocrine therapy for postmenopausal patients. There is also no clear guidance on subsequent treatment. From the results of several clinical trials, it may be better to sequentially use alternate drugs with different mechanism of action in sequential endocrine monotherapy. However, the advent of CDK4/6 inhibitors have resulted in a paradigm shift in the treatment of ER-positive/HER2-negative metastatic breast cancer. In this presentation, I would like to discuss about 4 issues to be solved in endocrine therapy for postmenopausal ER-positive/HER2-negative metastatic breast cancer. First, should CDK4/6 inhibitor in combination with endocrine agent be used as part of sequential endocrine therapy for all patients? Second, whether CDK4/6 inhibitor are more effective for use in 1st line therapy or subsequent treatment? Third, when using a CDK4/6 inhibitor after 1st line endocrine monotherapy, should it be changed to another endocrine agent or the same endocrine drug? Fourth, what is the optimal treatment in patients who have progressed during or after CDK4/6 inhibitor administration?" @default.
- W2896663068 created "2018-10-26" @default.
- W2896663068 creator A5024725726 @default.
- W2896663068 date "2018-10-01" @default.
- W2896663068 modified "2023-10-18" @default.
- W2896663068 title "Issue to be solved in the near future to determine optimal sequential endocrine therapy in metastatic breast cancer" @default.
- W2896663068 doi "https://doi.org/10.1093/annonc/mdy350" @default.
- W2896663068 hasPublicationYear "2018" @default.
- W2896663068 type Work @default.
- W2896663068 sameAs 2896663068 @default.
- W2896663068 citedByCount "0" @default.
- W2896663068 crossrefType "journal-article" @default.
- W2896663068 hasAuthorship W2896663068A5024725726 @default.
- W2896663068 hasBestOaLocation W28966630681 @default.
- W2896663068 hasConcept C121608353 @default.
- W2896663068 hasConcept C126322002 @default.
- W2896663068 hasConcept C143998085 @default.
- W2896663068 hasConcept C2775930923 @default.
- W2896663068 hasConcept C2776166826 @default.
- W2896663068 hasConcept C2778504769 @default.
- W2896663068 hasConcept C2780482068 @default.
- W2896663068 hasConcept C46699223 @default.
- W2896663068 hasConcept C530470458 @default.
- W2896663068 hasConcept C71315377 @default.
- W2896663068 hasConcept C71924100 @default.
- W2896663068 hasConcept C84606932 @default.
- W2896663068 hasConceptScore W2896663068C121608353 @default.
- W2896663068 hasConceptScore W2896663068C126322002 @default.
- W2896663068 hasConceptScore W2896663068C143998085 @default.
- W2896663068 hasConceptScore W2896663068C2775930923 @default.
- W2896663068 hasConceptScore W2896663068C2776166826 @default.
- W2896663068 hasConceptScore W2896663068C2778504769 @default.
- W2896663068 hasConceptScore W2896663068C2780482068 @default.
- W2896663068 hasConceptScore W2896663068C46699223 @default.
- W2896663068 hasConceptScore W2896663068C530470458 @default.
- W2896663068 hasConceptScore W2896663068C71315377 @default.
- W2896663068 hasConceptScore W2896663068C71924100 @default.
- W2896663068 hasConceptScore W2896663068C84606932 @default.
- W2896663068 hasLocation W28966630681 @default.
- W2896663068 hasOpenAccess W2896663068 @default.
- W2896663068 hasPrimaryLocation W28966630681 @default.
- W2896663068 hasRelatedWork W1901834169 @default.
- W2896663068 hasRelatedWork W1982896522 @default.
- W2896663068 hasRelatedWork W2060548158 @default.
- W2896663068 hasRelatedWork W2073293796 @default.
- W2896663068 hasRelatedWork W2087683876 @default.
- W2896663068 hasRelatedWork W2941264805 @default.
- W2896663068 hasRelatedWork W3004458066 @default.
- W2896663068 hasRelatedWork W3202689974 @default.
- W2896663068 hasRelatedWork W3203690439 @default.
- W2896663068 hasRelatedWork W4361889599 @default.
- W2896663068 hasVolume "29" @default.
- W2896663068 isParatext "false" @default.
- W2896663068 isRetracted "false" @default.
- W2896663068 magId "2896663068" @default.
- W2896663068 workType "article" @default.